Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DWD3V2
|
|||
| Drug Name |
AMB-05X
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| Company |
AmMax Bio redwood City, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Macrophage colony-stimulating factor 1 receptor (CSF1R) | Target Info | . | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| Viral protein interaction with cytokine and cytokine receptor | ||||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05349760) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AmMax Bio | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.